Mechanistic Clinical Trial of PCSK9 Inhibition for AAA
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Evolocumab, Placebo.
- Who it may be relevant to
- Registry conditions: Abdominal Aortic Aneurysm. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
A Randomized, Placebo-Controlled Mechanistic Clinical Trial of PCSK9 Inhibition With Evolocumab in Patients Undergoing Open Abdominal Aortic Aneurysm Repair
Overview
The goal of this mechanistic clinical trial is to assess whether lowering the low-density lipoprotein cholesterol (LDL-C) levels in the blood with the injections of the medication evolocumab will have any effect on the tissue or cells of patients with abdominal aortic aneurysm (AAA). Researchers will compare participants receiving evolocumab injections to participants receiving placebo injections to see how the tissue and cells of the aorta are affected by changes in LDL-C levels.
Detailed description
After being informed about the study and its potential risks, all patients giving informed consent will undergo a baseline visit and be randomized to received either evolocumab 140mg subcutaneously or placebo. This baseline visit includes a vital signs assessment, laboratory tests, medical history and medication review, a pregnancy test (if applicable), and training on how to perform drug injections. Participants will receive 3 doses/autoinjectors of study drug or placebo and be instructed to perform injections every 14 days starting 5 weeks prior to their scheduled AAA repair. If the baseline assessment occurs 5 weeks prior to their scheduled AAA, the first injection will be performed during this visit. Participants will have the option of coming back to the site for injections 2 and 3 or perform these injections at home under telehealth supervision. At the time of open AAA repair, participants will repeat laboratory tests and have a sample of aneurysm tissue taken. Participants will then have a follow up phone call 4 weeks after AAA repair to assess for any adverse events. At the conclusion of the study investigators will examine gene expression and protein levels in the aortic tissue to determine the impact of LDL-C lowering with evolocumab.
Interventions
- Drug Evolocumab
See arm description. - Drug Placebo
See arm description.
Primary outcome measures
- Interleukin (IL)-6 in myeloid derived monocytes/macrophages from in AAA tissue [Time frame: AAA Repair (Week 5)]
Secondary outcome measures (3)
- Matrix metalloproteinase (MMP)-9 in myeloid derived monocytes/macrophages from in AAA tissue [Time frame: AAA Repair (Week 5)]
- Infiltrating immune cell composition and their activation/inflammatory states in AAA tissue [Time frame: AAA Repair (Week 5)]
- Smooth muscle composition of AAA tissue [Time frame: AAA Repair (Week 5)]
Eligibility criteria
Inclusion criteria
- Abdominal aortic aneurysm (AAA) requiring open surgical repair
- Age > 18
- Provision of signed and dated informed consent form
- Stated willingness to comply with all study procedures and availability for the duration of the study
Exclusion criteria
- Prior use of a PCSK9 inhibitor (evolocumab, alirocumab, inclisiran) within 6 months of the baseline visit
- LDL-C < 40 mg/dL (within 3 months of baseline visit)
- Known allergy to PCSK9 inhibitor
- Aortic dissection
- Vascular connective tissue disorders
- Type I-III or V Thoraco-abdominal Aortic Aneurysm
- Vasculitis or inflammatory aneurysm
- Pregnant or lactating women
- Poorly controlled diabetes (A1C > 10%)
- Chronic kidney disease Stage 4/5 or End Stage Renal Disease (ESRD) on hemodialysis (HD)
- Liver Disease (alanine transaminase \[ALT\] or aspartate aminotransferase \[ALT\] > 3.0 x upper limits of normal) (within 3 months of baseline visit)
- Known latex or naturally rubber allergy
- Treatment with another investigational product within 30 days or 5 half-lives of the investigation drug before consent (whichever is longer) that would have an impact on endpoints associated with this trial.
- Any other condition that the Investigator feels prohibits participants' ability to comply with study or follow up.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Quadruple blind
- Primary purpose
- Other
Study locations
United States · 1 center
- Hospital of the University of Pennsylvania — Philadelphia
Identifiers
NCT: NCT06081153 · 852428 · R01HL166991